Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129760 · ClinicalTrials.gov registry record · NA
Glioblastoma Remote Monitoring and Care - Research Protocol
A NA study of Glioblastoma and Venous Thromboembolism, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06129760: Recruiting NA study of Glioblastoma and Venous Thromboembolism, sponsored by Case Comprehensive Cancer Center.
NCT06129760 is a NA study of Glioblastoma and Venous Thromboembolism that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06129760, a NA study of Glioblastoma and Venous Thromboembolism, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watch can detect these changes. Ultimately, this knowledge is being used to design proactive tools and signatures that can predict complications or symptom changes before they happen.
Conditions Studied
Interventions
- DEVICE Apple Watch
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06129760 shows while recruiting
NCT06129760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Apple Watch is the first listed.
NCT06129760 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06129760 about?
NCT06129760 is a clinical study titled "Glioblastoma Remote Monitoring and Care - Research Protocol". The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watc...
What is the current status of trial NCT06129760?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2024-04-30. Estimated completion is 2027-12.
What conditions does trial NCT06129760 study?
This clinical trial studies the following conditions: Glioblastoma, Venous Thromboembolism, Seizures.
What interventions are being tested in trial NCT06129760?
The interventions under investigation include: Apple Watch (DEVICE).
Who is sponsoring clinical trial NCT06129760?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129760 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06129760's enrollment target sits among peer trials
25 138th of 199 higher than 60 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI